{"id":396400,"date":"2020-12-09T09:03:28","date_gmt":"2020-12-09T14:03:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396400"},"modified":"2020-12-09T09:03:28","modified_gmt":"2020-12-09T14:03:28","slug":"sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/","title":{"rendered":"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SEATTLE, Dec.  09, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K53ul4p1mCOV8-L2qb8DbbPmzJxuqZXx88H_xOaDXTMKwcqIbVfNZQ7Qwiygt2igUlnUxsTeq9U99pgCU1wvDLGqN2gBisZo0lftaT1sBvA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>SEngine Precision Medicine<\/u><\/strong><\/a>, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today presented data from a study summarizing the predictive value of the PARIS\u00ae Test in breast cancer tumors as a poster session (PS04\/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020.<\/p>\n<p>This study highlighted the utility of the PARIS\u00ae Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in heterogeneous disease such as breast cancer. Authors found that the PARIS\u00ae Test:<\/p>\n<ul type=\"disc\">\n<li>Showed a high success rate (70.5%) in delivering a report ranking targeted, endocrine and chemotherapy agents in a clinically relevant timeframe for a cohort of metastatic, heavily pre-treated breast cancer patients.<\/li>\n<li>Showed high genomic concordance between known actionable biomarkers, such as PIK3CA and FGFR1\/FGFR2, and PARIS\u00ae Test organoid drug sensitivity.<\/li>\n<li>Identified candidate therapies in most patients lacking known druggable biomarkers.<\/li>\n<li>Guided oncologist treatment decisions in 50% of post-assay interventions.<\/li>\n<\/ul>\n<p>\u201cAt SEngine, our main commitment is to improve outcomes for people with cancer,\u201d stated Astrid Margossian, MD, PhD, Chief Medical Officer of SEngine Precision Medicine and lead author. \u201cThis commitment is exemplified by this exciting data utilizing our PARIS\u00ae Test across the breast cancer spectrum that showed a very strong predictive value between PARIS\u00ae Test drug responses and clinical benefit. The actionable report generated by the PARIS\u00ae Test influenced physicians and guided treatment decisions in 50% of cases.\u201d<\/p>\n<p>VK Gadi, MD, PhD, co-founder and Medical Advisor of SEngine Precision Medicine, added, \u201cManagement of advanced breast cancer has moved steadily away from rigid, canonical and stepwise care towards context-specific and personalized strategies that integrate clinical, pathologic, and genomic data. PARIS\u00ae adds the next dimension with functional responses to drugs and combinations to make the very best and most precise therapeutic choices for our patients.\u201d<\/p>\n<p>Carla Grandori, MD, PhD, co-founder and CEO of SEngine Precision Medicine, noted, \u201cFunctional testing is a new tool enabling oncologists to select treatments for patients where both the standard of care and current precision medicine approaches, such as DNA sequencing, fail. Oncologists at leading cancer centers across the United States and around the globe are adopting the\u00a0functional PARIS\u00ae Test\u00a0to bring personalized and precise treatments to patients\u00a0with the greatest unmet medical need across all solid tumor types.&#8221;<\/p>\n<p>Details related to the poster presentation are as follows:<br \/>Title: Clinical and genomic correlation of a CLIA certified organoid based functional test in breast cancer patients <br \/>Lead Author:\u00a0Astrid Margossian, MD, PhD<br \/>Senior Author: Carla Grandori, MD, PhD<br \/>Poster Session: Poster Session 4: Response Prediction Biomarkers I (PS04\/01)<br \/>Poster Session Date: December 9, 2020 at 8:00 am CT<\/p>\n<p>\n        <strong>About the PARIS\u00ae Test<\/strong>\u00a0<br \/>The PARIS\u00ae\u00a0Test is based on the capability to propagate patient-specific cancer\u00a0cells\u00a0as organoids\u00a0outside the body\u00a0and is applicable to all solid tumors\u00a0including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown\u00a0in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics.\u00a0For cancers\u00a0where\u00a0a treatment\u00a0path is not clear, such as\u00a0many metastatic and recurrent cancers,\u00a0the PARIS\u00ae Test provides crucial information to\u00a0treating physicians\u00a0to\u00a0match the right drug to the right patient.<\/p>\n<p>\n        <strong>About SEngine Precision Medicine<\/strong><br \/>\n        <br \/>SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells.\u00a0As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&amp;D in diagnostics and drug discovery. The Company is commercializing the PARIS\u00ae Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine\u2019s CLIA certified PARIS\u00ae Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical \/ pharma companies leveraging its precision oncology platform.<\/p>\n<p>Discover more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FdGLIZV9n8ClZEzOSVFQrdCkHVL8lm9Crc1RV9q1kahfhWzmZXnoQdlpNvUw_2UG6U-nTNTgUDbq8IyNFzgPPDq3FBITMC9MV7kUwJAIiAs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>SengineMedicine.com<\/u><\/strong><\/a>\u00a0and follow the latest news from SEngine on Twitter at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H-SMQxyZadpmzNeOehf9Gwzu--lLyvW9QnIV5esmkNUAhcaDszGeU_AKY94VfzUoXhB3d4285DOlxJvQyhjauth4LaUM6IYkIKkvaAOsvyI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>@SEngineMedicine<\/u><\/strong><\/a>\u00a0and on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0uv1unu8UgvhVQGkEMOqqDvXOFzwKQUb6f4H19Az5Ny7CVuNLCAtIIya9eoH1kxsgrs7l_v74iCfU3f9hP0JuSOdXuUzaChjEn3O032HsbDy2LlXouF2BUzDheUQuAJx\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>LinkedIn<\/u><\/strong><\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Stephanie Carrington<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HKcpJFPhXakoh3viPl2SSVWMbEgSQrNWb4VYXXJJXceGyiXOfbyj1xz-wHKiyFYdW_alSfFAV3S2wdhx5rg0ZhQ9GZN6OXotCywNll3axYAVlivgGbLqfwv8CNr8HP5xh9QiDlz8KbDFhdVQwaxHtQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>stephanie.carrington@westwicke.com<\/u><\/strong><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jUkOrJWkD8UiAC0ND2VwcB_-HJlCqON7hPubT8qWPnHpvgnKcS7742FPPNK7MQWwnFMMSnmX7PZTewtYShKzMr0QWLq7LtO570x6KXunnnFaSFS5JYkZlxmR2b8Jy-hByOAAMyvjYqhEmDJmnGbQUCf2qw390PhVk_l-QRIoKGW18jGD5e3vvmgt1KFtB0Ksk6_PPTjbabDlxnvr6KWwZAjkuB8g-u8S3JAQ89kO-PkVz3JNwMOBoUEbCgrhGZ7zTzKOuXvOYCh_WpdQjh8DxW4pXFLoBxYxgtPzyHf9WHaq_U7cBgTU3qkQxzdduRsnenR6Es6Xs8tTfcegiRFJry4-n-z8C7FJ1KWfnX4RxTy4mtl-3hAgUiI0OUmPpu1e\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/><\/a>646-277-1282<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/64ed32c3-6d7b-49e7-91ac-fbe0f635379f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today presented data from a study summarizing the predictive value of the PARIS\u00ae Test in breast cancer tumors as a poster session (PS04\/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020. This study highlighted the utility of the PARIS\u00ae Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in heterogeneous disease such as breast cancer. Authors found that the PARIS\u00ae Test: Showed a high success rate (70.5%) in delivering a report ranking targeted, endocrine and chemotherapy agents in a clinically relevant timeframe for a cohort of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396400","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today presented data from a study summarizing the predictive value of the PARIS\u00ae Test in breast cancer tumors as a poster session (PS04\/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020. This study highlighted the utility of the PARIS\u00ae Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in heterogeneous disease such as breast cancer. Authors found that the PARIS\u00ae Test: Showed a high success rate (70.5%) in delivering a report ranking targeted, endocrine and chemotherapy agents in a clinically relevant timeframe for a cohort of &hellip; Continue reading &quot;SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T14:03:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium\",\"datePublished\":\"2020-12-09T14:03:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/\"},\"wordCount\":695,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/\",\"name\":\"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=\",\"datePublished\":\"2020-12-09T14:03:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/","og_locale":"en_US","og_type":"article","og_title":"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","og_description":"SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today presented data from a study summarizing the predictive value of the PARIS\u00ae Test in breast cancer tumors as a poster session (PS04\/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020. This study highlighted the utility of the PARIS\u00ae Test, a CLIA certified functional drug sensitivity assay, to support clinical decision making in heterogeneous disease such as breast cancer. Authors found that the PARIS\u00ae Test: Showed a high success rate (70.5%) in delivering a report ranking targeted, endocrine and chemotherapy agents in a clinically relevant timeframe for a cohort of &hellip; Continue reading \"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T14:03:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium","datePublished":"2020-12-09T14:03:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/"},"wordCount":695,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/","name":"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=","datePublished":"2020-12-09T14:03:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTQ0NiMzODYyOTE0IzIxOTc1MjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-presents-data-summarizing-predictive-value-of-paris-test-in-breast-cancer-patients-at-2020-san-antonio-breast-cancer-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS\u00ae Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396400","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396400"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396400\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396400"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396400"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396400"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}